What can be taken with Vyvanse (lisdexamfetamine) to mitigate its side effect of decreased appetite?

Managing Decreased Appetite from Vyvanse (Lisdexamfetamine)

Decreased appetite is an expected and common side effect of Vyvanse, occurring in 27-39% of patients, and should be managed primarily through non-pharmacological strategies rather than adding additional medications. 1, 2

Understanding the Problem

• Decreased appetite is the most frequently reported adverse effect of Vyvanse across all age groups, affecting approximately one-third of patients 1, 3
• This side effect is dose-dependent—higher doses (50-70 mg) produce greater appetite suppression than lower doses (30 mg) 1
• Weight loss typically ranges from 2.8 to 4.3 pounds in adults after 4 weeks of treatment, with children experiencing similar patterns 1
• In pediatric patients treated consistently for 12 months, growth rate slowing occurs, with an average decrease of 13.4 percentile points in weight-for-age 1

Primary Management Strategy: Non-Pharmacological Interventions

Optimize meal timing and composition rather than adding appetite-stimulating medications:

• Schedule meals strategically around medication pharmacokinetics—eat a substantial breakfast before taking Vyvanse in the morning, and plan a larger dinner in the evening when drug effects are waning 4
• Implement small, frequent, calorie-dense meals throughout the day rather than three large meals, focusing on nutrient-rich foods that provide maximum nutrition in smaller volumes 4
• Prioritize high-calorie, high-protein foods during periods when appetite is present, particularly early morning and late evening 4
• Consider nutritional supplementation with protein shakes, smoothies, or meal-replacement beverages between meals to maintain caloric intake 4

Medication Adjustments to Consider

Before adding any additional medications, optimize the Vyvanse regimen itself:

• Evaluate current dosing—if the patient is on 70 mg and experiencing severe appetite suppression, consider dose reduction to 50 mg or 30 mg, as lower doses produce less appetite suppression while maintaining therapeutic benefit 1
• Assess whether the full dose is necessary—many patients achieve adequate ADHD control at submaximal doses with fewer side effects 3, 5
• Consider drug holidays—weekend or summer breaks in pediatric patients may allow catch-up growth, though this must be balanced against symptom control needs 1

Monitoring Requirements

Implement systematic tracking to prevent clinically significant weight loss:

• Weigh patients regularly—weekly during initial titration, then monthly once stable 4
• Track growth parameters in children and adolescents—measure height quarterly to monitor for growth trajectory changes 4
• Define intervention thresholds—if weight loss exceeds 5% of body weight despite interventions, medication adjustment or discontinuation should be considered 4
• Assess nutritional status and hydration at each follow-up visit, particularly in children 4

When to Switch Medications

Consider alternative ADHD medications if appetite suppression significantly impacts quality of life or causes clinically meaningful weight loss:

• Non-stimulant alternatives such as atomoxetine, guanfacine, or clonidine produce less appetite suppression than stimulants, though they have smaller effect sizes for ADHD symptoms 6, 4
• Atomoxetine specifically shows fewer effects on appetite and growth compared to stimulants and may be preferred when appetite suppression is treatment-limiting 6
• Alpha-2 agonists (clonidine or guanfacine) can be used as monotherapy or adjunctively with reduced Vyvanse doses to maintain efficacy while minimizing appetite effects 6, 4

What NOT to Do

Avoid these common pitfalls:

• Do not add appetite stimulants (e.g., cyproheptadine, mirtazapine)—there is no evidence supporting this approach for stimulant-induced appetite suppression, and it introduces additional side effects 4
• Do not ignore the problem—untreated appetite suppression can lead to significant growth impairment in children and nutritional deficiency in all age groups 1
• Do not assume tolerance will develop—while some side effects of Vyvanse diminish over time, appetite suppression often persists throughout treatment 2, 7
• Do not continue escalating doses if appetite suppression is already problematic—higher doses worsen this side effect 1

Special Populations

• Children require particularly vigilant monitoring due to growth concerns—consistently medicated pediatric patients show approximately 2 cm less height growth and 2.7 kg less weight gain over 3 years 1
• Patients with pre-existing eating disorders require especially careful monitoring and may not be appropriate candidates for Vyvanse 4
• Adolescents ages 13-17 experience mean weight losses of 2.7-4.8 pounds over 4 weeks at therapeutic doses 1